Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALPI | P09923 | 1/20 | 0.55 |
| ▸ | PKM | P14618 | 1/20 | 0.55 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.55 |
| ▸ | XIAP | P98170 | 1/20 | 0.55 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.55 |
| ▸ | KIF11 | P52732 | 13/20 | 0.51 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.47 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.47 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.47 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.44 |
| ▸ | GRB2 | P62993 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4398300 | 1.00 | ALPI (0.55) | ALPIPKMPTGS1XIAPSLC7A5 | |
| Hydrochloric Acid SCHEMBL2344672 | 0.98 | ALPI (0.53) | ALPIPKMPTGS1XIAPSLC7A5 | |
| Hydrochloric Acid SCHEMBL2344664 | 0.98 | ALPI (0.53) | ALPIPKMPTGS1XIAPSLC7A5 | |
| Bromide SCHEMBL2192294 | 0.98 | ALPI (0.53) | ALPIPKMPTGS1XIAPSLC7A5 | |
| Hydrochloric Acid SCHEMBL2340160 | 0.85 | KIF11 (0.49) | ALPIPKMPTGS1XIAPSLC7A5 | |
| Hydrochloric Acid SCHEMBL2340166 | 0.85 | KIF11 (0.49) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL19644692 | 0.83 | KIF11 (0.57) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL3196850 | 0.83 | TSHR (0.52) | SLC7A5KIF11SMN1; SMN2HIF1APTPN1 | |
| SCHEMBL346992 | 0.83 | TSHR (0.52) | SLC7A5KIF11SMN1; SMN2HIF1APTPN1 | |
| SCHEMBL1835145 | 0.83 | ALPI (0.55) | ALPIPKMPTGS1XIAPSLC7A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10668175-B2 | Cathepsin-binding compounds bound to a carrier and their diagnostic use | J. STEFAN INSTITUTE (SI) | 2020-06-02 | — | — | US | disclosed |
| EP-2723387-B1 | CATHEPSIN-BINDING COMPOUND BOUND TO A LIPOSOME AND ITS DIAGNOSTIC AND THERAPEUTIC USE | J STEFAN INST (SI) | 2018-04-18 | — | — | EP | disclosed |
| US-20180085479-A1 | CATHEPSIN-BINDING COMPOUNDS BOUND TO A CARRIER AND THEIR DIAGNOSTIC USE | J. STEFAN INSTITUTE (SI) | 2018-03-29 | — | — | US | disclosed |
| US-20180085479-A1 | CATHEPSIN-BINDING COMPOUNDS BOUND TO A CARRIER AND THEIR DIAGNOSTIC USE | J. STEFAN INSTITUTE (SI) | 2018-03-29 | — | — | US | disclosed |
| US-9827337-B2 | Cathepsin-binding compounds bound to a carrier and their diagnostic use | J. STEFAN INSTITUTE (SI) | 2017-11-28 | — | — | US | disclosed |
| US-9827337-B2 | Cathepsin-binding compounds bound to a carrier and their diagnostic use | J. STEFAN INSTITUTE (SI) | 2017-11-28 | — | — | US | disclosed |
| US-20140227175-A1 | CATHEPSIN-BINDING COMPOUNDS BOUND TO A CARRIER AND THEIR DIAGNOSTIC USE | J. STEFAN INSTITUTE (SI) | 2014-08-14 | — | — | US | disclosed |
| US-20140227175-A1 | CATHEPSIN-BINDING COMPOUNDS BOUND TO A CARRIER AND THEIR DIAGNOSTIC USE | J. STEFAN INSTITUTE (SI) | 2014-08-14 | — | — | US | disclosed |
| US-20140073662-A1 | Spirocyclic nitriles as protease inhibitors | SANOFI (FR) | 2014-03-13 | — | — | US | disclosed |
| US-8609681-B2 | Spirocyclic nitriles as protease inhibitors | SANOFI (FR) | 2013-12-17 | — | — | US | disclosed |
| WO-2012175223-A1 | CATHEPSIN-BINDING COMPOUNDS BOUND TO A CARRIER AND THEIR DIAGNOSTIC USE | J. STEFAN INSTITUTE (SI) | 2012-12-27 | — | — | WO | disclosed |
| US-20090275523-A1 | Spirocyclic nitriles as protease inhibitors | SANOFI-AVENTIS (FR) | 2009-11-05 | — | — | US | disclosed |
| EP-1490341-A1 | NOVEL ADAMANTANE DERIVATIVES | AstraZeneca AB (SE) | 2004-12-29 | — | — | EP | disclosed |
| US-20040142999-A1 | Novel compounds and compositions as cathepsin inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2004-07-22 | — | — | US | disclosed |
| EP-1397340-A2 | CHEMICAL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS AS CATHEPSIN S INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2004-03-17 | — | — | EP | disclosed |
| WO-2003080579-A1 | NOVEL ADAMANTANE DERIVATIVES | ASTRAZENECA AB (SE) | 2003-10-02 | — | — | WO | disclosed |
| WO-2002098850-A2 | CHEMICAL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS AS CATHEPSIN S INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2002-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275523-A1 | Spirocyclic nitriles as protease inhibitors | CTRL, SERPINB1, PREP | ALPI 816/4885PKM 2089/4885PTGS1 149/4885 |
| US-10668175-B2 | Cathepsin-binding compounds bound to a carrier and their diagnostic use | CTSB, CTSV, CTSE | ALPI 2979/4885PKM 4328/4885PTGS1 1103/4885 |
| US-20140227175-A1 | CATHEPSIN-BINDING COMPOUNDS BOUND TO A CARRIER AND THEIR DIAGNOSTIC USE | CTSB, CTSV, CTSE | ALPI 2979/4885PKM 4328/4885PTGS1 1103/4885 |
| US-20140073662-A1 | Spirocyclic nitriles as protease inhibitors | CTRL, SERPINB1, PREP | ALPI 816/4885PKM 2089/4885PTGS1 149/4885 |
| US-20040142999-A1 | Novel compounds and compositions as cathepsin inhibitors | CTSS, CTSB, CTSE | ALPI 723/4885PKM 4622/4885PTGS1 1681/4885 |
| US-20180085479-A1 | CATHEPSIN-BINDING COMPOUNDS BOUND TO A CARRIER AND THEIR DIAGNOSTIC USE | CTSB, CTSV, CTSE | ALPI 2979/4885PKM 4328/4885PTGS1 1103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.